Resmetirom

MECHANISM OF ACTION 

• Resmetirom selectively stimulated thyroid hormone receptor beta, a receptor found mainly in the liver. Following receptor activation, it enhanced metabolic pathways involved in the utilization and breakdown of fatty acids. This activity helped regulate hepatic lipid metabolism and reduced the buildup of excess fat within liver cells.

• Resmetirom also influenced cholesterol metabolism in the liver, promoting the processing and clearance of excess cholesterol. Through these combined effects on lipid and cholesterol handling, the drug helped decrease hepatic steatosis and was intended to improve liver injury and fibrosis associated with NASH.

PHARMACOKINETICS

Absorption

Resmetirom was absorbed after oral administration, and plasma concentrations reached their maximum within several hours. Food influenced the amount of drug reaching systemic circulation, although administration was possible with or without food. Following absorption, the drug entered the bloodstream and became available to exert its pharmacological effects.

Distribution

Once absorbed, resmetirom was distributed through the systemic circulation, with substantial exposure occurring in the liver, which represented its primary site of pharmacological activity. A large proportion of circulating resmetirom was bound to plasma proteins. This extensive protein binding affected the amount of unbound drug available in the circulation.

Metabolism

Resmetirom was extensively metabolized in the liver. Oxidative metabolism occurred mainly through cytochrome P450 pathways, with CYP2C8 playing a major role and CYP3A contributing to a lesser extent. The resulting metabolites underwent further metabolic processing, including conjugation, before being eliminated from the body.

Elimination

Elimination occurred predominantly through the feces, while only a smaller amount of the administered drug and its metabolites was recovered through the urine. The terminal half-life of resmetirom was measured in hours, although some metabolites remained in the circulation for longer periods. Overall, hepatic metabolism followed by biliary and fecal excretion represented the principal route by which resmetirom was cleared.

PHARMACODYNAMICS

Resmetirom was an orally active, selective agonist of the thyroid hormone receptor beta (THR-β), with its primary effects occurring in the liver. By stimulating THR-β, it influenced pathways responsible for hepatic lipid handling and promoted the oxidation of fatty acids. These actions helped decrease the accumulation of triglycerides within the liver and supported improvement in abnormal hepatic fat deposition associated with noncirrhotic nonalcoholic steatohepatitis (NASH) accompanied by moderate-to-advanced fibrosis. Resmetirom also produced favorable changes in circulating atherogenic lipid parameters, including reductions in LDL cholesterol and apolipoprotein B.

ADMINISTRATION

Resmetirom was given orally once each day. Administration was not dependent on meals, so the medicine could be taken either with food or on an empty stomach. The tablet was taken whole with liquid and was not intended to be crushed, chewed, or dissolved. Therapy was generally maintained over an extended period according to the prescribed treatment plan.

DOSAGE AND STRENGTH 

The daily dose of resmetirom was selected according to the patient's actual body weight. Patients weighing less than 100 kg received 80 mg once daily, whereas those weighing 100 kg or more received 100 mg once daily.

Resmetirom was supplied as oral tablets containing 60 mg, 80 mg, or 100 mg of the active ingredient. When resmetirom was administered together with medicines known to alter its exposure, the dosage could have required modification.

DRUG INTERACTIONS 

• Resmetirom was associated with several clinically relevant drug interactions. Concomitant use with certain statins could increase statin exposure and consequently raise the possibility of statin-related adverse effects, including muscle toxicity. This interaction was relevant to atorvastatin, rosuvastatin, simvastatin, and pravastatin, and appropriate monitoring or statin dose adjustment could have been necessary.

• Medicines that inhibited CYP2C8 could have increased the systemic exposure of resmetirom. Strong CYP2C8 inhibitors, including gemfibrozil, were generally avoided. When resmetirom was used with a moderate CYP2C8 inhibitor such as clopidogrel, a reduction in the resmetirom dose could have been required.

• Inhibitors of the hepatic transport proteins OATP1B1 and OATP1B3 could also have increased resmetirom concentrations. Their use therefore required consideration when treatment with resmetirom was initiated or continued.

• Resmetirom could also have increased exposure to warfarin, making closer monitoring of anticoagulation necessary when the two medicines were used together.

• Because resmetirom acted through thyroid hormone receptor pathways, it could have affected thyroid-related laboratory findings. Thyroid function was therefore monitored during treatment, particularly in individuals who were already receiving thyroid hormone replacement therapy.

FOOD INTERACTIONS 

Resmetirom could be administered either with meals or on an empty stomach. Food did not produce a clinically meaningful change in the drug’s overall exposure, so a specific dosing adjustment based on meals was generally not required. However, clinically relevant interactions could occur when resmetirom was used with other medicines, particularly statins, and these combinations required appropriate consideration during treatment.

CONTRAINDICATIONS

Resmetirom was contraindicated in individuals who had previously demonstrated hypersensitivity to resmetirom or to any ingredient present in the formulation. Its use was also not recommended in patients with decompensated cirrhosis because adequate safety and efficacy information had not been established for this group.

SIDE EFFECTS 

• Diarrhea.

• Nausea.

• Itching.

• Vomiting.

• Constipation.

• Abdominal discomfort or pain.

• Dizziness.

• Gallbladder-related disorders.

• Liver dysfunction.

OVER DOSE 

Clinical information concerning resmetirom overdose was limited. Taking more than the recommended amount could have increased the likelihood or severity of adverse reactions. Management of an overdose was primarily supportive and involved observation of the patient, assessment of clinical status, and treatment of symptoms when necessary. No specific antidote had been established for resmetirom toxicity.

TOXICITY 

Resmetirom had the potential to produce liver-related adverse effects, especially in patients who already had significant hepatic impairment. Treatment had been associated with elevations in liver enzymes and other findings suggestive of liver injury. Gallbladder complications were also considered a potential safety concern. Monitoring of liver function and attention to new or worsening hepatic or gallbladder-related symptoms were therefore important during treatment.